CD274 and non-small cell lung carcinoma: Accordingly, our novel data indicate higher levels of PD-L1+ AMs in milder COPD, suggesting that the AM-derived PD-L1, abundant in the earlier stages of COPD, may play a crucial role in NSCLC and represent a potential therapeutic target to prevent NSCLC onset and progression.